Rituxan in the treatment of cold agglutinin disease.

Detection of Cold Agglutinin with Cross-Reactive Idiotype Produced by Pneumonie Patients

Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis

A 57-year-old man with rheumatoid arthritis developed severe anemia during treatment with adalimumab plus methotrexate. Cold agglutinin disease was diagnosed because haptoglobin was undetectable, cold agglutinin was positive (1 : 2048), and the direct Coombs test was positive (only to complement). Although the cold agglutinin titer was normalized (1 : 64) after treatment with prednisolone (0.7 ...

Cold agglutinin disease.

Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune hemolytic anemia. We reviewed the clinical and pathologic features, prognosis, and management in the literature and describe our institutional experience to improve strategies for accurate diagnosis and treatment. Retrospective analysis identified 89 patients from our institution with cold...

Cold agglutinin disease associated with mycoplasma infection in an individual with type 2 diabetes: An atypical case

Cold Agglutinin Disease is a hemolytic anemia associated with cold reactive autoantibodies. Although the acute form of cold agglutinin disease can be attributed to autoimmune or infectious diseases and lymphoproliferative diseases, it has,to the best of our knowledge, so far,never been reported as secondary to Mycoplasma pneumonia in a type 2 diabetic individual. In this paper, we report a case...

Cold agglutinin disease in sepsis: A rare entity

Cold agglutinin disease (CAgD) is a type of autoimmune hemolytic anemia which generally occurs in adults and is characterized by the presence of IgM antibodies directed against polysaccharide antigens on red blood cell surface. A 16-year-old male, having clinical picture of sepsis and anemia, presented to the Emergency Department of our Institute in an Hemodynamically unstable condition. Invest...

Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity

Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement-mediated hemolysis in a patient whose hemodynamic status deteriorated in spite of supportive blood transfusions and therapeutic plasma exchange.